A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Part of paid clinical trials in Dilworth, Minnesota.

Sponsor
Incyte Corporation
Study ID
NCT07588139
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.

Key Dates

Start date
May 18, 2026
Status verified
Jun 2026
Primary completion
Sep 3, 2026
Completion
Sep 19, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Ruxolitinib 1.5 % Cream
    Ruxolitinib cream applied topically twice daily.
  • Experimental: Cohort 2: Povorcitinib
    Povorcitinib will be administered at the protocol defined dose.
  • Experimental: Cohort 3: Povorcitinib
    Povorcitinib will be administered at the protocol defined dose.

Primary Outcome Measure

Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib [ Time Frame: Up to Day 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Axis ClinicalsDilworthMinnesota56529-

Find similar trials in Dilworth, MN

By research site
Axis Clinicals· Dilworth, MN

Related Studies